> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# NeuroPace Lost Routine Surgeon Contact After Distribution Exit — Its CEO Says It Can Stay Out
- URL: https://www.bullished.co/neuropace-lost-routine-surgeon-contact-after-distribution-exit-its-ceo-says-it-can-stay-f246aa9c/
- Published: 2026-11-12T22:56:24.000Z
- Updated: 2026-11-12T22:56:24.000Z
- Description: The company cut its revenue outlook to $91 million–$92 million as disrupted implant accounts and sales-team changes slowed growth.
- Author: Matteo Parrino
- Tags: Earnings, NPCE, Industry: Healthcare

[NeuroPace](https://www.bullished.co/tag/npce/), which makes an implanted device that monitors brain activity and delivers electrical pulses to help prevent seizures, lost routine surgeon contact after leaving diagnostic-product distribution, Chief Executive Officer Joel Becker said on Thursday’s earnings call. The company cut its 2026 revenue forecast to [$91 million–$92 million](https://www.sec.gov/Archives/edgar/data/0001528287/000152828726000037/exhibit991%5Fq32026earningsr.htm?ref=bullished.co), from $99.5 million–$101.5 million, in its results release.

## Relationships Needed Regular Visits

The distribution business had put representatives in operating rooms earlier in patients’ diagnostic evaluations. Becker said management expected the relationships it built to preserve access to neurosurgeons after the transition in late 2025 and early 2026.

Access survived, but regular contact required more work. Distribution had supplied “a more routine presence and engagement structurally,” Becker said. Being there repeatedly helped representatives capture additional implant cases.

The effect took time to reach revenue because adult focal epilepsy patients typically spend six to nine months moving from identification to implant. Reduced contact became more apparent in third-quarter results.

Asked by a Wolfe Research analyst whether NeuroPace could bring back the distribution business, Becker defended the exit. He said the company had corrected sales-team attention to those accounts and their performance had normalized: “it's not something that we need to have.”

Management’s rationale remains that representatives’ time should become more valuable as NeuroPace develops its own products and pursues expanded treatment uses.

## Big Accounts Compounded The Disruption

Third-quarter RNS revenue rose [1.4% to $22.9 million](https://www.sec.gov/Archives/edgar/data/0001528287/000152828726000037/exhibit991%5Fq32026earningsr.htm?ref=bullished.co), from $22.6 million a year earlier. Total revenue fell 1.1% to $23.1 million as lower service revenue outweighed that growth; both periods exclude the former DIXI Medical distribution business.

Chief Financial Officer Patrick Williams told a JPMorgan analyst that major implant accounts also included some of the largest former distribution customers. Reassigning commercial personnel at the same time compounded the disruption.

Other problems at large centers included staffing changes, physician availability and limited diagnostic capacity. Becker told a Mizuho analyst that most affected patients had been delayed, rather than permanently lost. He said the sales restructuring had involved people changing roles without costing the company customer relationships.

The midyear overhaul flattened sales management, changed territory leadership and centralized some clinical-support functions to redirect work toward sales. Becker said those changes were complete, with additional commercial hiring planned for 2027.

The RNS System currently treats U.S. adults whose focal epilepsy—seizures beginning in a specific part of the brain—is uncontrolled by medication. NeuroPace sells initial implants and replacements through a direct sales team focused on epilepsy specialists and neurosurgeons.

Becker said medium-sized accounts and community referrals had improved, but disruption among high-volume customers obscured those gains.

## Recovery Forecast Excludes Expanded Approval

Williams said the lower annual outlook reflected both the third-quarter shortfall and cautious expectations for fourth-quarter improvement. Management’s forecast implies approximately $23 million–$24 million in fourth-quarter total revenue, with about 5% RNS growth at the midpoint.

The company expects approximately 15% core RNS revenue growth in 2027: 10%–15% in the first half, accelerating to 15%–20% in the second half and toward 20% at year-end. Those expectations exclude contributions from potential approval to treat idiopathic generalized epilepsy and from service revenue.

NeuroPace expects to amend its FDA application for that expanded use around year-end. Management is planning for a [180-day review](https://www.businesswire.com/news/home/20261112017708/en/NeuroPace-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Revised-Full-Year-Guidance?ref=bullished.co) and potential approval by midyear 2027\. It also sees potential second-quarter 2027 approval for Remote Care, which would let physicians program devices through telehealth.

Becker expects the commercial recovery to unfold over several quarters: restoring contact must first translate into patients completing evaluations and reaching implant.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [NeuroPace results release (Form 8-K, EX-99)](https://www.sec.gov/Archives/edgar/data/0001528287/000152828726000037/exhibit991%5Fq32026earningsr.htm?ref=bullished.co) — SEC EDGAR
- [NeuroPace Inc.: Q3 Earnings Snapshot | wfaa.com](https://www.wfaa.com/article/syndication/associatedpress/neuropace-inc-q3-earnings-snapshot/616-985cd40a-556e-47e8-bdb3-51b259deffdb?ref=bullished.co) — Associated Press
- [NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance](https://www.businesswire.com/news/home/20261112017708/en/NeuroPace-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Revised-Full-Year-Guidance?ref=bullished.co) — businesswire.com

### More on NeuroPace

- [NeuroPace Cuts Sales Outlook To $91 Million–$92 Million As Major Accounts Stumble](https://www.bullished.co/neuropace-cuts-sales-outlook-to-91-million-92-million-as-major-accounts-stumble-12cd30b5/)

[All NeuroPace (NPCE) coverage →](https://www.bullished.co/tag/npce/)